Eli Lilly and Company · Physical Exposure and Transition
Pharma Manufacturing · climate + nature risk across the portfolio. Site-level transition models are available on each location page.
Portfolio overview
33 sites · 12 countriesLocations
Portfolio map · click a tile above to reframe
33 sites · 12 countries
Dependant transition pathways
API + chemicals supply chain
Scope 3 · cat 1Reference pathway
Active ingredient synthesis is the largest S3 bucket. Decarbonisation pace of bulk chemicals + fine chemicals manufacturers in Asia caps progress.
framework:SBTi Chemicals (sector pathway), PSCI Energy Working Group
No global scenario — this pathway plays out at the site level. Select a site to see the local transition pathway.
Your exposure
Sector-generic framing shown above — company-specific exposure narrative pending.
HFC refrigerants + propellants
Scope 1 + Scope 3 · cat 4 + cat 11Reference pathway
Cold-chain HFC leaks + MDI propellants. Kigali Amendment phase-down sets the schedule.
framework:Kigali Amendment to Montreal Protocol
No global scenario — this pathway plays out at the site level. Select a site to see the local transition pathway.
Your exposure
Sector-generic framing shown above — company-specific exposure narrative pending.
Aviation
Scope 3 · cat 6 + cat 4Reference pathway
Clinical trial sample shipping + global team travel. Cold-chain air freight is doubly energy-intensive.
framework:IATA Fly Net Zero 2050
Best0%
Realistic50%
Worst150%
Aviation CO2 (commercial) · % of 2019 absolute CO2 · base 2019
Source: IATA Fly Net Zero, ICAO LTAG, BAU (~3% pa growth)
Source: IATA Fly Net Zero, ICAO LTAG, BAU (~3% pa growth)
Your exposure
Sector-generic framing shown above — company-specific exposure narrative pending.